Compare Dyne Therapeutics Inc. Common Stock (DYN) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs MINISO Group Holding Ltd — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while MINISO Group Holding Ltd trades at $10.34 (market cap $2.89B). The key difference: Dyne Therapeutics Inc. Common Stock and MINISO Group Holding Ltd are close in size by market cap, and MINISO Group Holding Ltd pays a 6.71% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and MINISO Group Holding Ltd for 25 Days on average.
| DYN | MNSO | |
|---|---|---|
Market Cap | $2.86B | $2.89B |
Volume | 3,341,579 | 1,658,211 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $22.75 |
52-Week Low | $14.60 | $8.60 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $2.18B | $3.76B |
Dividend Yield | — | 6.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MNSO trades at $9.92, up 1.95% with a bullish technical signal despite mixed earnings history. The company shows solid fundamentals with $21.44B revenue, 5.35% net margin, and attractive valuation ratios including P/E of 16.11 and P/S of 0.86. Recent CFO share purchases and analyst optimism (60% buy rating) support positive sentiment, though earnings misses in three of the last four quarters highlight execution risks amid competitive retail pressures.
The outlook remains cautiously optimistic given MNSO's valuation appeal and growth potential, but investors should monitor earnings consistency and overseas margin pressures. Key opportunities include domestic expansion and operational optimization, while risks involve volatile quarterly performance and intense retail competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
